A news conference and a conference call for analysts, investors and media will be held on Wednesday, 5 January 2020 at 13.30 EET at Orion's head office, address Orionintie 1A, Espoo. Participants are requested to present a photo ID at the head office reception.
A link to the live webcast will be available on Orion's website at www.orion.fi/en/investors. A recording of the event will be available on the website later the same day.
To participate the conference call, please dial:
Finland: +358 9 817 103 10
Sweden: +46 8 566 426 51
UK: +44 33 3300 0804
USA: +1 855 857 0686
The silent period preceding the publication is ongoing and continues until the disclosure.
Tuukka Hirvonen, Investor Relations & Corporate Communications, Orion Corporation
tel. +358 (0)10 426 2721
Orionintie 1A, FI-02200 Espoo, Finland
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion’s net sales in 2018 amounted to EUR 977 million and the company had about 3,200 employees at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.